Proteomics International Laboratories (PIQ) Q3 2026 TU earnings summary

Executive summary

• Completed a strategic review, shifting focus to commercial execution and capital discipline.

• Discontinued the direct-to-consumer business model and engaged potential distribution partners in Australia and the USA.

• Continued validation and refinement of Promarker Endo and Promarker Eso assays.

• Undertook an organisational restructure, reducing headcount by 25% to improve efficiency.

• Leadership transition with new CEO and CFO appointments, and retirement of founder and a non-executive director.

Financial highlights

• Cash outflows from operations were $2.6 million for the quarter ended 31 March 2026.

• Cash and cash equivalents stood at $5.7 million at quarter end, down from $7.7 million in December 2025.

• Received $0.7 million from the exercise of options during the quarter.

• Operating cash outflows included $1.3 million for staff/admin, $0.7 million for R&D, and $0.7 million for manufacturing, operations, and marketing.

• Payments to related parties totaled $389,000, including $130,000 in retirement entitlements.

Outlook and guidance

• Strategic roadmap targets commercialisation, innovation, scaling, and sustainable long-term value over three years.

• Focus on distributor partner models for faster adoption and capital efficiency.

• Progressing reimbursement pathways in Australia and the USA, combining early private pay with evidence generation.